Search
for
Sort by
Research 331–360 of 1000+
- Chemoprävention des Prostatakarzinoms - Ein Plädoyer
- Editor's Choice
- The keratoacanthoma: A review
- Clascoterone: First Approval
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- The Rotterdam Study: 2014 objectives and design update
- The Rotterdam Study: 2012 objectives and design update
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Loose anagen hair of childhood: The phenomenon of easily pluckable hair
- Ritlecitinib: First Approval
- Hair toxic and essential trace elements in children with autism spectrum disorder
- TINEA CAPITIS
- Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
- Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old
- Quality of life in South African Black women with alopecia: a pilot study
- Diagnostic and Therapeutic Assessment of Frontal Fibrosing Alopecia
- Hypertension in Children and Adolescents
- A review of hormonal therapy for female pattern (androgenic) alopecia
- Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
- Erosive Pustular Dermatosis of the Scalp
- Panfolliculoma: Report of the Youngest Case and Literature Review of Its Histopathologic Variants
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
- Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- Assessment of Knowledge, Attitudes, and Awareness Levels Regarding Skin Health, Sun Protection Habits, and Cosmetic Procedures Among Pregnant Women
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata